R&D / Product Development
Aurobindo Pharma Reports Positive Phase 3 Results for Omalizumab Biosimilar BP11
NSE
auropharma
BSE
524804
Aurobindo Pharma’s subsidiary CuraTeQ Biologics has announced positive top-line results from its Phase 3 clinical study of Omalizumab biosimilar BP11, demonstrating strong comparability and efficacy.
PRICE-SENSITIVE TRIGGER
Event: Clinical Trial Update (Phase 3 Results)
Type: R&D / Product Development
Impact: Positive
Immediate Effect: Boost to biosimilar pipeline and future regulatory approval prospects
What Happened ?
CuraTeQ Biologics (wholly owned subsidiary of Aurobindo Pharma) announced:
- BP11 is a biosimilar of Xolair (Omalizumab)
- Positive Phase 3 trial results for BP11
Key clinical highlights
Study Details
- Patients: 608
- Locations: ~80 sites
- Regions: Europe + India
Primary Endpoint
- Change in ISS7 score at Week 12
- Successfully met
Results
- High comparability with reference drug (Xolair)
- Confidence intervals within predefined margins
- Demonstrated:
- Efficacy
- Safety
- Dose-level consistency
Additional Outcomes
- Relative potency endpoint achieved
- Strong statistical robustness
- Supports regulatory filings
Next Steps
- Filing planned with:
- EMA (Europe)
- FDA (USA)
Target Indications
- Chronic Spontaneous Urticaria (CSU)
- Allergic Asthma
- CRSwNP (Chronic Rhinosinusitis with Nasal Polyps)
Timeline: Expected by Q2 2026
Risk Analysis
Key Risks
- Regulatory rejection/delay
- Competitive biosimilars
- Pricing pressure in biosimilar market
- Time lag to commercialization
Worst Case Scenario
Delay in approvals lead to revenue delay
Risk Level: Medium
Company Commentary
- Strong validation of clinical strategy
- High-quality biosimilar development
- Confidence in regulatory success
Official Exchange Filing: Aurobindo Pharma Ltd